Group items tagged

Bipolar disorder can be a very challenging mental illness to deal with. It is characterized by severe mood swings, from manic highs to depressive lows. Many people with bipolar disorder struggle to live normal, productive lives. However, there are various treatments available that can help manage the symptoms of this condition and improve quality of life. In this article, we will discuss the different treatments for bipolar disorder and how to properly deal with the symptoms. MEDICATIONS One of the most common treatments for bipolar disorder is medication. There are a variety of different medications that can be used to treat the symptoms of bipolar disorder. The type of medication that is prescribed will depend on the individual's specific situation. Some common medications that are used to treat bipolar disorder include mood stabilizers, antipsychotics, and antidepressants. However, it is important to note that these are serious medications and should only be taken under the supervision of a qualified mental health professional. So, never attempt to take these medications on your own.

The Medicines and Healthcare products Regulatory Agency (MHRA) has reminded healthcare professionals prescribing aripiprazole to alert patients about its possible side effects, following a rise in the number of reports of gambling disorder associated with the drug. Patients taking aripiprazole, which is used for the treatment of schizophrenia and bipolar disorder, are at risk of developing unusual urges or cravings that they cannot resist, including behaviours such as addictive gambling, excessive eating or spending, or an abnormally high sex drive. The regulator has received 69 reports of gambling or gambling disorder suspected to be caused by aripiprazole in the last 14 years via the Yellow Card Scheme, out of which 32 were received between 1 January and 31 August this year. Alison Cave, MHRA Chief Safety Officer, said: "The number of reports for suspected gambling and other impulsive behaviours associated with aripiprazole are small in comparison to the frequency with which it is prescribed, but the consequences for any patient developing these conditions can be significant."

Upload Press Release for free of ✔ Electronics ✔ Business ✔ Medical ✔ Energy ✔ Technology industry. Submit PR Free on weSRCH.com

The Department of Health and Social Care (DHSC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) have authorised community pharmacies throughout the UK to dispense original full packs of Valproate-containing medicines upon prescription. The necessary changes in regulations came into effect on 11 October which was strongly supported by 85 per cent of respondents concerned about risks to the unborn baby if valproate-containing medicines are used in pregnancy. The decision was made to ensure patients receive safety warnings and pictograms, including a patient card and the Patient Information Leaflet (PIL), contained in the manufacturer's original full pack. Valproate is a treatment for epilepsy and bipolar disorder but is also associated with birth defects and neurological disabilities.

Smoking increases the risk of developing schizophrenia and depression, a report by academics from the University of Bristol published on 20 June claims. It says smoking raises the risk of developing schizophrenia by between 53 per cent and 127 per cent and the risk of developing depression by from 54 per cent to 132 per cent. The authors of the report say more research is needed to identify why this is the case and that more evidence is needed to understand its impact on other mental health conditions such as anxiety or bipolar disorder. The evidence, presented at the Royal College of Psychiatrist's international congress, has been shared with the government which is currently developing a new Tobacco Control Plan for publication later this year. Action on Smoking and Health (ASH) said: "Rates of smoking are much higher among people with mental health conditions than those without, and among England's six million smokers there are an estimated 230k smokers with severe mental illness (e.g., schizophrenia and bi-polar disorder) and 1.6 million with depression and anxiety."

Adding to the growing evidence of global medicine shortages, a new study has revealed that the European generic medicines market is "not in shape" to help Europe meet its public health priorities. In the past decade, the rate of generic medicines withdrawals has risen by 12 per cent, while there has been a three per cent decrease in the launch of generic products, as per Teva Pharmaceuticals' recent analysis of IQVIA data. Within the mental therapeutic area, seven per cent of generic products disappeared between 2013 and 2023, while there was a seven per cent decrease in the availability of generic cancer medicines in just six years (2017-2022). These medicines were listed on the Union List of Critical Medicines to help avoid potential shortages, as the European Commission (EC) said this could cause "significant harm to patients and pose important challenges to health systems." While mature generic products constitute the majority of the List, they remain susceptible to withdrawals, despite containing products crucial for safeguarding Europe's public health, the Teva analysis report noted. Since 2013, the number of generic products for the treatment of schizophrenia and bipolar disorder has declined by 25 per cent, with Hungary and Bulgaria experiencing the biggest loss at 83 per cent and 58 per cent respectively.